Anti-VEGF therapy has been utilized in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, polypoidal choroidal vasculopathy, retinopathy of prematurity, neovascular glaucoma, hepatocellular carcinoma, and prostate cancer [224,225,226,227,228,229,230]. The gene discussed is VEGFA; the disease is wet macular degeneration.